Congratulations from GBG to the entire ASCENT-05 team on the following successes:
- First Patient In in Germany
Second Patient In in Spain
Short profil: Study of Sacituzumab Govitecan and Pembrolizumab versus treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy
You can find more details here
